Current Liabilities decreased faster than Lipocine Inc 's Cash & cash equivalent, this led to improvement in Lipocine Inc 's Quick Ratio to 11.25, Quick Ratio remained below Lipocine Inc average.

Within Major Pharmaceutical Preparations industry 93 other companies have achieved higher Quick Ratio than Lipocine Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 172 to 412.

Explain Quick Ratio?
How much Cash & cash equivalents LPCN�s has?
What are LPCN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

LPCN Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	42.74 %	94.5 %	67.11 %	22.13 %	-20.57 %
Y / Y Cash & cash equivalent Change	29.72 %	25.41 %	-30.98 %	-23.67 %	-20.46 %
Quick Ratio MRQ	11.25	9.78	5.91	7.84	12.38
LPCN's Total Ranking	# 412	# 172	# 386	# 348	# 55
Seq. Current Liabilities Change	-18.19 %	-0.01 %	30.92 %	33.29 %	11.48 %
Seq. Cash & cash equivalent Change	-5.91 %	65.63 %	-1.33 %	-15.64 %	-9.04 %

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 94
Healthcare Sector	# 142
Overall Market	# 412

Quick Ratio Statistics
High	Average	Low
943.6	36.06	0
(Sep 30 2012)		(Jun 30 2013)

Financial Statements
Lipocine Inc 's Current Liabilities	$ 2 Millions	Visit LPCN's Balance sheet
Lipocine Inc 's Cash & cash equivalent	$ 23 Millions	Visit LPCN's Balance sheet
Source of LPCN's Sales		Visit LPCN's Sales by Geography

Cumulative Lipocine Inc 's Quick Ratio

LPCN's Quick Ratio for the trailling 12 Months

LPCN Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	54.98 %	35.68 %	13.49 %	-16.91 %	-27.98 %
Y / Y Cash & cash equivalent TTM Growth	-1.33 %	-13.14 %	-23.6 %	-16.42 %	-14.99 %
Quick Ratio TTM	8.62	8.62	9.39	12.02	13.54
Total Ranking TTM	# 3804	# 2542	# 2189	# 2383	# 2441
Seq. Current Liabilities TTM Growth	7.34 %	17.04 %	16.4 %	5.99 %	-6.03 %
Seq. Cash & cash equivalent TTM Growth	7.33 %	7.4 %	-9.01 %	-5.93 %	-5.51 %

Quick ratio ranking by company, industry and sector >> Back to LPCN Financial Strength Comparisons >> Go to Compare LPCN Quick Ratio to its Competitors

News about Lipocine Inc Quick Ratio

Lipocines Breakthrough Bioequivalence Study Results Pave the Way for Revolutionary Pharmacological Treatment

Lipocine Inc., a renowned biopharmaceutical company, has recently announced groundbreaking results from various studies, demonstrating the bioequivalence of its oral drug candidate, LPCN 1154, to the intravenous (IV) form of brexanolone. These results have the potential to revolutionize the treatment approach for postpartum depression (PPD) and other related conditions. In this article, we will delve into the significance of these findings and their potential impact on the pharmaceutical industry.Bioequivalence Study Results:In a pivotal pharmacokinetic (PK) study, Lipocine successfully demonstrated bioequivalence of its oral formulation of LPCN 1154 compared to the IV form of brexanolone. The positive topline results obtained from this study are monumental, as they validate the effectiveness of LPCN 1154 as an alternative treatment for PPD. This pioneering drug, developed using Lipocine s proprietary technology platform, has shown the potential to augment therapeutic options for patients suffering from this debilitating condition.

On the trailing twelve months basis In Spite of the decline in Current Liabilities in the Q2 2026 to $2.07 millions, cumulative Quick Ratio remained unchanged at 8.62 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 430 other companies have achieved higher Quick Ratio than Lipocine Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2026 from 2542 to 3804.

Explain Quick Ratio?
How much Cash & cash equivalents LPCN�s has?
What are LPCN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 431
Healthcare Sector	# 879
Within the Market	# 3804

trailing twelve months Quick Ratio Statistics
High	Average	Low
317.27	12.16	0.98
(Jun 30 2013)		(Sep 30 2018)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Climb Bio Inc	30.86	$ 183.123 Millions	$ 5.934 Millions
Indaptus Therapeutics Inc	29.61	$ 15.554 Millions	$ 0.525 Millions
Crinetics Pharmaceuticals Inc	29.41	$ 2,350.275 Millions	$ 79.915 Millions
Spyre Therapeutics Inc	28.48	$ 1,100.000 Millions	$ 38.620 Millions
Curanex Pharmaceuticals Inc	28.17	$ 2.938 Millions	$ 0.104 Millions
Onkure Therapeutics Inc	28.04	$ 186.284 Millions	$ 6.643 Millions
Ligand Pharmaceuticals Incorporated	27.33	$ 1,277.438 Millions	$ 46.736 Millions
Shattuck Labs Inc	26.94	$ 208.300 Millions	$ 7.731 Millions
Cryoport inc	26.87	$ 785.860 Millions	$ 29.244 Millions
Roivant Sciences Ltd	26.82	$ 7,607.076 Millions	$ 283.603 Millions
Palvella Therapeutics Inc	26.23	$ 313.381 Millions	$ 11.947 Millions
Upstream Bio Inc	26.16	$ 261.307 Millions	$ 9.988 Millions
Rallybio Corporation	26.02	$ 92.800 Millions	$ 3.567 Millions
Assembly Biosciences Inc	25.95	$ 608.475 Millions	$ 23.445 Millions
Arbutus Biopharma Corp	25.84	$ 92.625 Millions	$ 3.585 Millions
Immix Biopharma Inc	25.49	$ 238.715 Millions	$ 9.364 Millions
Boundless Bio Inc	25.00	$ 194.230 Millions	$ 7.768 Millions
Sionna Therapeutics Inc	24.88	$ 268.300 Millions	$ 10.782 Millions
Prothena Corporation Public Limited Company	24.72	$ 288.193 Millions	$ 11.658 Millions
Zenas Biopharma Inc	24.28	$ 1,597.761 Millions	$ 65.818 Millions
Neuphoria Therapeutics Inc	23.89	$ 19.866 Millions	$ 0.832 Millions
Innoviva Inc	23.77	$ 1,118.871 Millions	$ 47.064 Millions
Pepgen Inc	23.51	$ 211.674 Millions	$ 9.005 Millions
Kailera Therapeutics Inc	23.41	$ 1,958.240 Millions	$ 83.651 Millions
Equillium Inc	23.07	$ 57.164 Millions	$ 2.478 Millions
Relmada Therapeutics Inc	21.72	$ 217.731 Millions	$ 10.023 Millions
Keros Therapeutics Inc	21.20	$ 257.606 Millions	$ 12.153 Millions
Protagonist Therapeutics inc	21.05	$ 782.576 Millions	$ 37.181 Millions
Stablecoin Development Corporation	20.76	$ 7.122 Millions	$ 0.343 Millions
Rhythm Pharmaceuticals Inc	20.65	$ 596.183 Millions	$ 28.868 Millions

Date modified: 2026-09-26T07:12:58+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.